NCT04162990

Brief Summary

The specific study aims:

  1. 1.To investigate whether the brain function is affected by the past life experiences, such as lifestyle and physiology-related factors in SMC.
  2. 2.To examine whether the lifestyle remodeling could improve SMC's cognitive function and modulate the reactivity of inflammatory factors, leading to significantly slow down the disease progression to MCI or dementia.
  3. 3.To investigate the lasting duration of the intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 14, 2019

Completed
5 days until next milestone

Study Start

First participant enrolled

November 19, 2019

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
Last Updated

November 14, 2023

Status Verified

November 1, 2023

Enrollment Period

3.3 years

First QC Date

September 19, 2019

Last Update Submit

November 12, 2023

Conditions

Keywords

Subjective Memory ComplaintAlzheimer's diseasemild cognitive impairmentNeuroinflammationlifestyle

Outcome Measures

Primary Outcomes (6)

  • Changes in Electroencephalogram (EEG) performance.

    The amplitude, latency of MMN (mismatch negativity), N2, and the P3 components will be used to evaluate the memory and inhibitory control ability. Other EEG time-frequency analysis will be used to examine the changes of different frequency bands, such as theta, alpha, beta, and gamma.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Concentration change from baseline in the blood biochemical indices. (Total Tau, Aβ1-40, Aβ1-42, IL-1b, TNF-a, IL-6, TGF-b, BDNF, insulin, and ApoE4)

    Blood samples will use an enzyme-linked immunosorbent assay (ELISA) to assay the concentrations of Tau, Beta Amyloid (Aβ)1-40, Aβ1-42, interleukin-1β (IL-1β), tumor necrosis factor (TNF)-⍺, Interleukin-6 (IL-6), transforming growth factor (TGF)-β, brain-derived neurotrophic factor (BDNF), insulin, etc. The apolipoprotein E4 (ApoE4) genotype will also be evaluated.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change score of the Chinese version Verbal Learning Test (CVVLT).

    A nine-item of CVVLT (total recall, delayed recall) will be applied to measure the participant's memory ability, with a higher score indicating better performance.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change score of the WMS-III logical memory test part A.

    WMS-III logical memory test part A (immediate recall, delayed recall) will be applied to measure the participant's memory ability. The maximum score is 25 for each recall trial, with a higher score indicating better performance.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change score of the Taylor Complex Figure Test (TCFT).

    TCFT (immediate recall, delayed recall) will be applied to measure the participant's memory ability. The maximum score is 36 for each recall trial, with a higher score indicating better performance.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change score of the Digit Span Backward Test.

    The Digit Span Backwards Task will be applied to measure the participant's working memory ability. A higher score indicating better performance.

    baseline, post-treatment (6 months), follow-up (12 months)

Secondary Outcomes (8)

  • Subjective memory complaint survey.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change scores of EuroQol-5 Dimension (EQ-5D).

    baseline, post-treatment (6 months), follow-up (12 months)

  • Lifestyle activities survey.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Physiological parameter (Blood pressure and blood glucose) survey.

    baseline, post-treatment (6 months), follow-up (12 months)

  • Change score of the Cognitive Abilities Screening Instrument (CASI).

    baseline, post-treatment (6 months), follow-up (12 months)

  • +3 more secondary outcomes

Study Arms (2)

Lifestyle remodeling

EXPERIMENTAL
Behavioral: Lifestyle remodeling Intervention

Does Comparator: regular treatment

ACTIVE COMPARATOR
Behavioral: Does Comparator: regular treatment

Interventions

Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.

Lifestyle remodeling

Participants in this group would be treated as usual, which contained the healthy education.

Does Comparator: regular treatment

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age over 50 years old.
  • Diagnosed with subjective memory complaint (SMC) and with lower cognitive activities and physical activities.
  • Voluntary to sign the Informed Consent Form.

You may not qualify if:

  • Participants or first-degree relatives diagnosed with mental diseases.
  • Participants have history of severe neurological diseases or brain injury led to loss of consciousness.
  • Participants have diagnosis of cardiovascular disease.
  • Participants have History of alcohol, Nicotine, or substance dependence.
  • Participants suffer from visual, hearing degradation (including Hearing aid user).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taipei Veterans General Hospital

Taipei, Beitou District, 11217, Taiwan

Location

MeSH Terms

Conditions

Alzheimer DiseaseCognitive DysfunctionNeuroinflammatory Diseases

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersCognition DisordersInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pei-Ning Wang, M.D.

    Taipei Veterans General Hospital, Taiwan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2019

First Posted

November 14, 2019

Study Start

November 19, 2019

Primary Completion

March 1, 2023

Study Completion

March 1, 2023

Last Updated

November 14, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations